3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
complex biomarker-driven oncology trials for Gilead Sciences, Kite Pharma, and emerging biotech companies SOUTH SAN FRANCISCO, Calif., March 02, 2026 BUSINESS WIRE )--3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms. Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors. "Rebeca brings a strong track record of building and leading clinical operations in both established biopharma organizations and emerging biotechnology companies," said Behzad Kharabi, M.D., chief medical officer of 3T Biosciences. "Her pragmatic, quality-focused approach and experience delivering complex early phase clinical trials will be an important asset as we progress our pipeline of TCR-based therapeutics for
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance [Yahoo! Finance]Yahoo! Finance
- Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia [Yahoo! Finance]Yahoo! Finance
- Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of ColumbiaBusiness Wire
- Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- GILD's page on the SEC website